David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Mikkael A. Sekeres, MD, on MDS and CMML Study Results: SWOG S1117

Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses an additional analysis of a phase II study of azacitidine combined with lenalidomide or with vorinostat vs azacitidine monotherapy in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia (Abstract 908).

Leukemia

Richard M. Stone, MD

Richard M. Stone, MD, on AML: Results of the RATIFY Trial

Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discusses this international prospective study on the survival impact of midostaurin, a multikinase inhibitor, in newly diagnosed acute myeloid leukemia with FLT3 mutations (Abstract 6).

Multiple Myeloma

James N. Kochenderfer, MD

James N. Kochenderfer, MD, on Preventing Progressive Malignancy After Stem Cell Transplant

James N. Kochenderfer, MD, of the National Cancer Institute, discusses a clinical trial of allogeneic T cells expressing an anti-CD19 chimeric antigen receptor, which caused remissions of B-cell cancers after stem cell transplant, without causing graft-vs-host disease (Abstract LBA1).

Multiple Myeloma

S. Vincent Rajkumar, MD

S. Vincent Rajkumar, MD, on Multiple Myeloma: Newly Approved Drugs

S. Vincent Rajkumar, MD, of the Mayo Clinic, summarizes a special FDA-sponsored session on the three myeloma drugs that were approved this November––daratumumab, ixazomib, and elotozumab––and their current and future roles in treating the disease.

Lymphoma

Stephen J. Schuster, MD

Stephen J. Schuster, MD, on CD19+ Lymphomas: Sustained Remissions in Relapsed or Refractory Disease

Stephen J. Schuster, MD, of the University of Pennsylvania, discusses the findings of a study of chimeric antigen receptor modified T cells directed against CD19 in patients with relapsed or refractory disease (Abstract 183).

Feb

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Mikkael A. Sekeres, MD, on MDS and CMML Study Results: SWOG S1117

Richard M. Stone, MD, on AML: Results of the RATIFY Trial

James N. Kochenderfer, MD, on Preventing Progressive Malignancy After Stem Cell Transplant

S. Vincent Rajkumar, MD, on Multiple Myeloma: Newly Approved Drugs

Stephen J. Schuster, MD, on CD19+ Lymphomas: Sustained Remissions in Relapsed or Refractory Disease

Can R-CHOP–Like Therapy Effectively Treat Late-Relapse DLBCL

Bicistronic CAR T-Cell Therapy Demonstrates Clinical Activity in Relapsed or Refractory B-Cell ALL

Predicting Response to KRAS G12C Inhibitors in NSCLC

Rising Advanced Prostate Cancer Rates in California Follow Changes to Recommendations

Trastuzumab Pertuzumab Plus Eribulin or Taxane in Locally Advanced or Metastatic Breast Cancer